Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms

March 10, 2022 11:05:00
  • Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
  • The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
  • By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://cnw.fm/8bk1Y)
  • With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year

Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes.

In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

Receive Text Alerts from CBDWireText “Cannabis” to 21000

For more information please visit https://www.cbdwire.com and or https://CBDWire.News

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.